Original Article

You have full text access to this OnlineOpen article

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma†

A report from the Children's Oncology Group

  1. Alexander J. Chou MD1,
  2. Eugenie S. Kleinerman MD2,
  3. Mark D. Krailo PhD3,4,
  4. Zhengjia Chen MS4,
  5. Donna L. Betcher5,
  6. John H. Healey MD6,
  7. Ernest U. Conrad III MD7,
  8. Michael L. Nieder MD8,
  9. Michael A. Weiner MD9,
  10. Robert J. Wells MD10,
  11. Richard B. Womer MD11,
  12. Paul A. Meyers MD1,‡,*,
  13. on behalf of the Children's Oncology Group

Article first published online: 27 JUL 2009

DOI: 10.1002/cncr.24566

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5339–5348, 15 November 2009

Additional Information

How to Cite

Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., Womer, R. B., Meyers, P. A. and on behalf of the Children's Oncology Group (2009), Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma. Cancer, 115: 5339–5348. doi: 10.1002/cncr.24566

Author Information

  1. 1

    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California

  4. 4

    Children's Oncology Group, Arcadia, California

  5. 5

    Section of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota

  6. 6

    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

  7. 7

    Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington

  8. 8

    Blood and Marrow Transplantation, All Children's Hospital, St. Petersburg, Florida

  9. 9

    Division of Pediatric Oncology, Columbia Presbyterian College of Physicians & Surgeons, New York, New York

  10. 10

    Department of Pediatric Hematology/Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  11. 11

    Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

  1. ‡

    Fax: (212) 717-3447

*Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065

  1. †

    Preliminary results presented at the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 3, 2008.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 27 JUL 2009
  3. Manuscript Accepted: 9 APR 2009
  4. Manuscript Revised: 8 APR 2009
  5. Manuscript Received: 16 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (371K)

References

  • 1
    Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer. 2007; 109: 1646-1653.
    Direct Link:
  • 2
    Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 1154-1161.
    Direct Link:
  • 3
    Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer. 2006; 106: 403-412.
    Direct Link:
  • 4
    McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer. 2006; 46: 345-350.
    Direct Link:
  • 5
    Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience. Cancer. 2005; 104: 1100-1109.
    Direct Link:
  • 6
    del Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M. Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol. 2005; 27: 42-45.
  • 7
    Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21: 2011-2018.
  • 8
    Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14: 1126-1134.
  • 9
    Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449-453.
  • 10
    Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993; 14: 286-292.
  • 11
    MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989; 81: 935-938.
  • 12
    Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992; 10: 1310-1316.
  • 13
    Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62: 101-107.
  • 14
    MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994; 2: 391-396.
  • 15
    Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995; 9: 927-938.
  • 16
    Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995; 18: 93-99.
  • 17
    Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995; 17: 181-193.
  • 18
    Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999; 14: 121-128.
  • 19
    Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006; 2: 333-343.
  • 20
    Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep. 2006; 8: 310-315.
  • 21
    Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006; 6: 123-133.
  • 22
    Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 633-638.
  • 23
    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011.
  • 24
    Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
  • 25
    Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol. 2003; 25: 840-841.
  • 26
    Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998; 16: 2452-2458.
  • 27
    Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003; 39: 488-494.
View Full Article (HTML) Get PDF (371K)